Related Experiment Video
Updated: Mar 15, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma
Julio Lambea1, Urbano Anido2, Olatz Etxániz3
1Hospital Clínico Universitario Lozano Blesa, Avenida San Juan Bosco, 15, 50009, Zaragoza, Spain. juliolambea@yahoo.es.
Abstract:
Sequential targeted therapies are the standard of care for patients with metastatic renal cell carcinoma (mRCC). Several drugs are available for patients whose disease progresses while they receive initial tyrosine kinase inhibitor (TKI) therapy; these include nivolumab (an inhibitor of PD-1 receptor), everolimus (an inhibitor of the mechanistic target of rapamycin) or additional TKIs. Until now, there has been no clinical evidence to support the use of one strategy versus another, so investigators and physicians rely on experience, judgement and findings from molecular analyses to select the appropriate treatment. However, with the arrival of nivolumab and cabozantinib that provide an overall survival higher than other alternative treatments, therapeutic strategies may have changed. Here, we discuss findings from preclinical and clinical studies that might help clinicians to choose the optimal treatment approach for patients with mRCC who progress to initial therapy.
Insights
For metastatic renal cell carcinoma (mRCC) progressing on initial therapy, nivolumab and cabozantinib offer improved survival. This review discusses evidence to guide optimal sequential treatment selection for mRCC patients.
Area of Science:
- Oncology
- Medical Science
Background:
- Metastatic renal cell carcinoma (mRCC) treatment relies on sequential targeted therapies.
- Several options exist for patients progressing on initial tyrosine kinase inhibitor (TKI) therapy, including nivolumab, everolimus, and other TKIs.
- Historically, limited clinical evidence guided the choice between these sequential treatments.
Purpose of the Study:
- To review preclinical and clinical findings relevant to sequential therapy selection in mRCC.
- To provide guidance for clinicians on choosing optimal treatment for mRCC patients after initial therapy failure.
Main Methods:
- Review of preclinical studies.
- Analysis of clinical trial data.
- Discussion of molecular findings impacting treatment selection.
Main Results:
- Nivolumab and cabozantinib have emerged as treatments offering superior overall survival compared to other alternatives.
- Emerging evidence suggests a shift in therapeutic strategies for advanced mRCC.
Conclusions:
- The arrival of nivolumab and cabozantinib necessitates a re-evaluation of standard mRCC treatment algorithms.
- Clinicians can utilize updated preclinical and clinical data to optimize sequential therapy selection for mRCC patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:56Treatment Resistent Cancers